The Comparison of Newly Diagnosed Invasive Breast Patient Cohorts in Genomics Evidence Neoplasia Information Exchange Biopharma Collaborative ( GENIE ‐ BPC ) and Other Real‐World Databases
Pharmacoepidemiology and Drug Safety · 2024
DOI: 10.1002/pds.5851 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2024. Verfasst von Xinyue Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Epidemiology, Biostatistics and Research Decision Sciences, Merck & Co., Inc., West Point, Pennsylvania, USA. Hauptthemen laut MEDLINE: Breast Neoplasms, Databases, Factual, Genomics, SEER Program. Die Arbeit nennt 24 Literaturangaben. Gefördert von: California Department of Public Health, CDC HHS, NCI NIH HHS.
Abstract (Originalsprache)
Background
Oncology databases that integrate genomic and clinical data have become valuable resources for precision medicine. However, the generalizability of these databases has not been comprehensively assessed.
Objectives
To describe the demographics, clinical characteristics, treatments, and overall survival of breast cancer cohorts in GENIE‐BPC and three other databases.
Methods
This study utilized GENIE‐BPC, SEER, SEER‐Medicare, and Merative MarketScan Research Databases. Women with invasive breast cancer were identified through EHR, cancer registries or ICD‐9/10‐CM codes. The ages were 18+ years or per database requirement. Treatments were based on EHR or HCPCS/NDC codes in claims. Overall survival was estimated as time from diagnosis to death.
Results
Of female breast cancer patients in GENIE‐BPC ( n = 775), SEER ( n = 548 336), SEER‐Medicare ( n = 68 914), and Marketscan ( n = 109 499) databases, the median ages at initial diagnosis were 44, 62, 74, and 57 years, respectively. A greater proportion of patients in GENIE‐BPC, compared to SEER/SEER‐Medicare, had higher nuclear grades (%III–%IV: 57% vs. 26%/24%), advanced disease stage (%IV: 25.3% vs. 5%/3.6%), percent of triple negative breast cancer (19.7% vs. 10.2%/8.5%), and receipt of chemotherapy (85.0% vs. NA/22.3%). The 1‐, 3‐, and 5‐year overall survival rates were lower in GENIE‐BPC (78.5%, 60.5%, 55.5%) than in SEER (95.8%, 89.5%, 85.5%) and SEER‐Medicare (91.6%, 81.4%, 75.0%).
Conclusion
Breast cancer patients in GENIE‐BPC were younger, had more advanced disease, had a higher proportion of triple negative breast cancer and recipients of chemotherapy, and had poorer overall survival. Researchers must use statistical adjustment when extrapolating results (e.g., biomarker prevalence) from GENIE‐BPC to the larger breast cancer population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Epidemiology, Biostatistics and Research Decision Sciences, Merck & Co., Inc., West Point, Pennsylvania, USA.
- Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, Florida, USA.
ORCID-Profile: Xinyue Liu, Mehmet Burcu
Förderung
- California Department of Public Health
- CDC HHS
- NCI NIH HHS
- Centers for Disease Control and Prevention
- National Cancer Institute
Zitieren
APA
Liu, X., Alipour, G. H., Shao, C., Burcu, M., Bortnichak, E., Vo, T., & Yu, C. L. (2024). The Comparison of Newly Diagnosed Invasive Breast Patient Cohorts in Genomics Evidence Neoplasia Information Exchange Biopharma Collaborative ( GENIE ‐ BPC ) and Other Real‐World Databases. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.5851
Vancouver
Liu X, Alipour GH, Shao C, Burcu M, Bortnichak E, Vo T, et al. The Comparison of Newly Diagnosed Invasive Breast Patient Cohorts in Genomics Evidence Neoplasia Information Exchange Biopharma Collaborative ( GENIE ‐ BPC ) and Other Real‐World Databases. Pharmacoepidemiology and Drug Safety. 2024. doi:10.1002/pds.5851
BibTeX
@article{Liu2024,
author = {Liu, Xinyue and Alipour, Golnoosh Haris and Shao, Changxia and Burcu, Mehmet and Bortnichak, Edward and Vo, Thao and Yu, Chu-Ling},
title = {The Comparison of Newly Diagnosed Invasive Breast Patient Cohorts in Genomics Evidence Neoplasia Information Exchange Biopharma Collaborative ( GENIE ‐ BPC ) and Other Real‐World Databases},
journal = {Pharmacoepidemiology and Drug Safety},
year = {2024},
doi = {10.1002/pds.5851}
}
EUVIMED